Companies › Amylyx Pharmaceuticals
3 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 3, 1 Phase 1; Metabolic and endocrine, Neurology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Avexitide Glucagon-like peptide 1 receptor antagonist | GLP1R | Phase 3 | Post Bariatric Hypoglycemia | Feb 2027 |
| AMX0035 Proprietary formulation of taurursodiol and sodium phenylbutyrate | – | Phase 2 | Wolfram Syndrome; Type 1 Diabetes (T1D) | May 2028 |
| AMX0114 Antisense oligonucleotide targeting calpain-2 mRNA | CAPN2 | Phase 1 | ALS | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06747468 | Avexitide | Phase 3 | Post Bariatric Hypoglycemia | Metabolic and endocrine | Feb 2027 |
| NCT06665165 | AMX0114 | Phase 1 | ALS | Neurology | Feb 2027 |
| NCT05676034 | AMX0035 | Phase 2 | Wolfram Syndrome | Metabolic and endocrine | May 2028 |
| NCT07699380 | AMX0035 | Phase 2 | Type 1 Diabetes (T1D) | Metabolic and endocrine | Dec 2029 |
Cash and short-term investments of $768m on 2026-09-30; operating cash outflow about $137m a year; runway about 67 months at that burn, to May 2032; 3 of 3 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 16 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Kailera Viking Therapeutics Beijing QL Biopharmaceutical MBX Biosciences Rhythm Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.